EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program

Stefan de Vogel iD, John D Seeger iD, Alejandro Arana iD, Andrea V Margulis iD, Lisa J McQuay, Susana Perez-Gutthann iD, Jesper Hallas iD, Nina Sahlertz Kristiansen, Marie Linder iD, Ingvild Odsbu, Brandon Suehs, Yihua Xu und 3 weitere

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5799 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Stefan de Vogel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance, Astellas Pharma B.V., Leiden, The Netherlands. Hauptthemen laut MEDLINE: Thiazoles, Product Surveillance, Postmarketing, Urinary Bladder, Overactive, Acetanilides. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many factors contribute to developing and conducting a successful multi‐data source, non‐interventional, post‐authorization safety study (NI‐PASS) for submission to multiple health authorities. Such studies are often large undertakings; evaluating and sharing lessons learned can provide useful insights to others considering similar studies.

Objectives

We discuss challenges and key methodological and organizational factors that led to the delivery of a successful post‐marketing requirement (PMR)/PASS program investigating the risk of cardiovascular and cancer events among users of mirabegron, an oral medication for the treatment of overactive bladder.

Results

We provide context and share learnings, including sections on research program collaboration, scientific transparency, organizational approach, mitigation of uncertainty around potential delays, validity of study outcomes, selection of data sources and optimizing patient numbers, choice of comparator groups and enhancing precision of estimates of associations, potential confounding and generalizability of study findings, and interpretation of results.

Conclusions

This large PMR/PASS program was a long‐term commitment from all parties and benefited from an effective coordinating center and extensive scientific interactions across research partners, scientific advisory board, study sponsor, and health authorities, and delivered useful learnings related to the design and organization of multi‐data source NI‐PASS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazolesProduct Surveillance, PostmarketingUrinary Bladder, OveractiveAcetanilidesHumansPharmacoepidemiologyCardiovascular DiseasesResearch DesignUrological AgentsInformation Sources

Stichwörter der Autor:innen

learningsmulti‐data source non‐interventional post‐authorization safety studiesorganization and methodologyresearch collaboration

Substanzen

mirabegronThiazolesAcetanilidesUrological Agents

Autor:innen und Institutionen

  • Pharmacovigilance, Astellas Pharma B.V., Leiden, The Netherlands.
  • Epidemiology, Optum, Boston, Massachusetts, USA.
  • Epidemiology, RTI Health Solutions, Barcelona, Spain.
  • Epidemiology, RTI Health Solutions, Research Triangle Park, Durham, North Carolina, USA.
  • Public Health, University of Southern Denmark, Odense, Denmark.
  • Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet, Solna, Sweden.

ORCID-Profile: Stefan de Vogel, John D Seeger, Alejandro Arana, Andrea V Margulis, Susana Perez-Gutthann, Jesper Hallas, Marie Linder

Förderung

  • Astellas Pharma US

Zitieren

APA

de Vogel, S., Seeger, J. D., Arana, A., Margulis, A. V., McQuay, L. J., Perez-Gutthann, S., Hallas, J., Kristiansen, N. S., Linder, M., Odsbu, I., Suehs, B., Xu, Y., Uribe, C., Appenteng, K., & Robinson, N. J. (2024). Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5799

Vancouver

de Vogel S, Seeger JD, Arana A, Margulis AV, McQuay LJ, Perez-Gutthann S, et al. Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5799

BibTeX
@article{deVogel2024,
  author = {de Vogel, Stefan and Seeger, John D and Arana, Alejandro and Margulis, Andrea V and McQuay, Lisa J and Perez-Gutthann, Susana and Hallas, Jesper and Kristiansen, Nina Sahlertz and Linder, Marie and Odsbu, Ingvild and Suehs, Brandon and Xu, Yihua and Uribe, Claudia and Appenteng, Kwame and Robinson, Noah Jamie},
  title = {Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5799}
}
Kostenlos starten →